Amerikanische Gesellschaft für Hirudotherapie

Chronic Glossitis (Investigational Adjunct)

Highly investigational adjunct for chronic glossitis; case reports only; addressing underlying nutritional, infectious, or allergic causes remains primary.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for chronic glossitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). No controlled trials. Evidence-based first-line management is identifying and treating the underlying cause: iron, B12, or folate deficiency; candidiasis with antifungals; geographic tongue (reassurance and topical anesthetics for discomfort); allergic or irritant contact (eliminate triggers); and biopsy of any suspicious lesion to exclude malignancy.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Oral placement is NOT standard or appropriate for leech therapy — most reports describe submental or cervical placement
  • Risk of bleeding into a richly vascular oral or perioral area
Wer dies nicht in Betracht ziehen sollte
  • Patients who have not been worked up for iron, B12, folate deficiency or candidiasis
  • Patients with any suspicious lesion that has not been biopsied (oral cancer screening is mandatory)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
  • Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
Was Sie Ihren Kliniker fragen sollten
  • Have I been tested for B12, folate, iron deficiency, candidiasis, and Sjogren disease?
  • Has a suspicious lesion been ruled out by biopsy?
  • Where exactly will the leeches be placed (oral placement is generally inappropriate)?
  • What is the published evidence base for leeches in glossitis?
  • How will success be measured — symptom improvement, appearance, both?
  • What is the plan if I do not improve?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Tongue swelling causing breathing or swallowing difficulty
  • Persistent white or red patch, ulcer, or lump on the tongue lasting more than 3 weeks
  • Unexplained tongue pain with hearing loss or facial numbness

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for glossitis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace workup for nutritional deficiency, infection, or malignancy.
  • It does not address the most common reversible causes (B12, iron, folate, candida).
  • It does not have controlled-trial evidence in this indication.
  • It does not differentiate benign glossitis from oral cancer — that requires biopsy.

Clinical Profile

Category
ent
ICD-10
K14.0, K14.1, K14.9
Safety tier
high

Evidence Summary

Chronic glossitis (atrophic, geographic, median rhomboid) management per oral medicine guidance includes correcting nutritional deficiencies (B12, folate, iron, riboflavin, niacin), evaluating for candidiasis (especially in immunocompromised patients), removing irritants (sharp dental edges, allergens), and assessing for systemic disease (autoimmune disorders, celiac disease, malabsorption). No controlled clinical trial of leech therapy for chronic glossitis has been published; its use is investigational and mechanistic only. Direct intraoral leech application is contraindicated due to mucosal anatomy and aspiration risk. Evidence is grade D.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Krashenyuk AI (2010)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Acute glossitis with airway compromise
  • Suspected oral or tongue malignancy
  • Untreated B12 or iron deficiency
  • Active oral candidiasis or HIV-related oral disease
  • Any intraoral or tongue placement

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Chronic Glossitis (Investigational Adjunct) — Hirudotherapy Evidence | ASH